Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.

Authors

null

Anupama Deepa Kumar

University of California-San Diego, La Jolla, CA

Anupama Deepa Kumar , Michelle Padilla , Lin Liu , Minya Pu , Emily Pittman , Dimitrios Tzachanis , Sarah Marie Larson , Nina Shah , Carolyn M. Mulroney , Edward David Ball , Aaron Seth Rosenberg , Caitlin Costello

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03590652

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8041)

DOI

10.1200/JCO.2022.40.16_suppl.8041

Abstract #

8041

Poster Bd #

465

Abstract Disclosures